Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
Table 4
Endpoints.
Overall (n = 45)
FEP (n = 22)
MEM (n = 10)
TZP (n = 13)
P value
Primary endpoint
Treatment success
22/38 (58)
11/20 (50)
4/8 (50)
7/10 (70)
0.65
Secondary endpoints
Duration of definitive therapy, median (IQR)
7.0 (1–13)
7.2 (3.7–10.8)
10.2 (5.9–14.5)
8.1 (4.7–11.4)
0.11
Duration of empiric antibiotics, median (IQR)
6.0 (1–11)
9.5 (−2.6–21.7)
7.2 (1.9–12.5)
8.7 (0.43–17.0)
0.83
Received guideline recommended therapy
8 (17.8)
2 (9.1)
2 (20)
4 (30.8)
0.26
In-hospital mortality
8 (17.8)
2 (9.1)
4 (40)
2 (15.4)
0.10
Hospital LOS, median (IQR)
19 (3–35)
26.1 (7.1–45.1)
28.8 (12.1–45.5)
23.2 (6.8–39.5)
0.75
ICU LOS, median (IQR)
13 (−1.5–27.5)
15.2 (3.4–26.9)
20.7 (7.8–33.6)
15.5 (5.7–25.2)
0.53
30-day readmission rates
9 (20)
3 (15)
2 (33.3)
4 (40)
0.47
Readmission due to infectious causes
4 (8.9)
0
2 (100)
2 (50)
0.11
Hospital-acquired CDI
2 (4.4)
2 (10)
0
0
0.34
Exploratory endpoints
Microbiologic clearance
10/12 (83.3)
5 (83.3)
1 (50)
4 (100)
0.30
Days to septic shock resolution, mean (SD)
3.3 (0.65–6.0)
3.8 (0.6–7.0)
0.9 (−0.1–2.0)
3.8 (4.4–3.1)
0.42
n (%) unless otherwise indicated. treatment success was only calculated in 38 patients as 7 patients had missing labs. IQR: interquartile range; LOS: length of stay; CDI: Clostridioides difficile infection; FEP: cefepime; MEM: meropenem; TZP: piperacillin-tazobactam.
